Customization: | Available |
---|---|
CAS No.: | 171099-57-3 |
Shelf Life: | 3 Years |
Suppliers with verified business licenses
Audited by an independent third-party inspection agency
Product Name: | Oritavancin |
Synonyms: | Oritavancin (LY333328);(4R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-a-L-arabinohexopyranosyl)-N3-(p-(p-chlorophenyl)benzyl)vancomycin;(4''R)-22-O-(3-Amino-2,3,6-trideoxy-3--methyl-alpha-L-arabino-hexopyranosyl)-N3''-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]vancomycin;LY 333328;Orbactiv;Oritavancin (Lyophilized Powder For IV Infusion);(1S,2R,18R,19R,22S,25R,28R,40R)-22-(2-Amino-2-oxoethyl)-2-[(3-amino-2,3,6-trideoxy-3-methyl-α-L-arabino-hexopyranosyl)oxy]-5,15-dichloro-48-{[2-O-(3-{[(4'-chloro-4-biphenylyl)methyl]amino}-2,3,6-t |
CAS: | 171099-57-3 |
MF: | C86H97Cl3N10O26 |
MW: | 1793.12 |
Product Categories: | API |
Mol File: | 171099-57-3.mol |
Molecular Structure: | ![]() |
A semisynthetic glycopeptide used (as its bisphosphate salt) for the treatment of acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms including MRSA.
Uses
Investigated for use/treatment in bacterial infection and skin infections/disorders.